ArticleClinical research in cardiology : official journal of the German Cardiac Society2019
Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- An oncologic cardiotoxicity masquerading as ST-elevated myocardial infarction: a case report.European heart journal. Case reports · 2026Article
- Cardiotoxicity in Breast Cancer Therapy: Risks, Mechanisms, and Prevention Strategies.Medical sciences (Basel, Switzerland) · 2025Review
- Exercise, cancer, and the cardiovascular system: clinical effects and mechanistic insights.Basic research in cardiology · 2025Review
- Review
- Relevance of Cardiovascular Exercise in Cancer and Cancer Therapy-Related Cardiac Dysfunction.Current heart failure reports · 2024Review
- Transient Left Ventricular Dysfunction from Cardiomyopathies to Myocardial Viability: When and Why Cardiac Function Recovers.Biomedicines · 2024Review
- The Impact of Chemotherapy on Cardiovascular Mortality across Breast Cancer Subtypes.Current oncology (Toronto, Ont.) · 2024Article
- Review
- Acute heart failure presentation, management, and outcomes in cancer patients: a national longitudinal study.European heart journal. Acute cardiovascular care · 2023Article
- Serial Non-Invasive Myocardial Work Measurements for Patient Risk Stratification and Early Detection of Cancer Therapeutics-Related Cardiac Dysfunction in Breast Cancer Patients: A Single-Centre Observational Study.Journal of clinical medicine · 2023Article
- Ventricular Sigmoid Septum as a Risk Factor for Anthracycline-Induced Cancer Therapeutics-Related Cardiac Dysfunction in Patients With Malignant Lymphoma.Circulation reports · 2022Article
- Myocardial Work Brings New Insights into Left Ventricular Remodelling in Cardio-Oncology Patients.International journal of environmental research and public health · 2022Article
- Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications.Heart failure reviews · 2022Review
- Cardiac imaging in cardiotoxicity: a focus on clinical practice.Heart failure reviews · 2021Review
- Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer.Molecular and cellular biochemistry · 2021Review
- The mRNA expression ofMolecular medicine reports · 2021Article
- Article
- Clinical Profile and Prognosis of a Real-World Cohort of Patients With Moderate or Severe Cancer Therapy-Induced Cardiac Dysfunction.Frontiers in cardiovascular medicine · 2021Article
- Anthracycline Induced Cardiac Disorders in Childhood Acute Lymphoblastic Leukemia: A Single-Centre, Retrospective, Observational Study.Frontiers in pharmacology · 2021Article
- Three-dimensional speckle-tracking echocardiography for the global and regional assessments of left ventricle myocardial deformation in breast cancer patients treated with anthracyclines.Clinical research in cardiology : official journal of the German Cardiac Society · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLeft ventricular (LV) dysfunction due to anthracycline-induced cardiotoxicity (AIC) has been believed to be irreversible. However, this has not been confirmed and standard medical treatment for heart failure (HF) including renin-angiotensin inhibitors and β-blockers may lead to its recovery. METHODS AND
resultsWe thus retrospectively studied 350 cancer patients receiving anthracycline-based chemotherapy from 2001 to 2015 in our institution. Fifty-two patients (14.9%) developed AIC with a decrease in LV ejection fraction (LVEF) of 24.1% at a median time of 6 months [interquartile range (IQR) 4-22 months] after anthracycline therapy. By multivariate analysis, AIC was independently associated with cardiac comorbidities including ischemic heart disease, valvular heart disease, arrhythmia, and cardiomyopathy [odds ratio (OR) 6.00; 95% confidence interval (CI) 2.27-15.84, P = 0.00044), lower baseline LVEF (OR per 1% 1.09; 95% CI 1.04-1.14, P = 0.00034). During the median follow-up of 3.2 years, LV systolic dysfunction recovered among 33 patients (67.3%) with a median time of 4 months (IQR 2-6 months), which was independently associated with the introduction of standard medical treatment for HF (OR 9.39; 95% CI 2.27-52.9, P = 0.0014) by multivariate analysis.
conclusionEarly initiation of standard medical treatment for HF may lead to LV functional recovery in AIC.
Indexed as
Identifiers
30367208What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.